ULTRAGENYX PHARMACEUTICAL INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$71.03 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-08
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$71.03M.
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was $57.10M.
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $29.79M, a 43.27% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$19.86M, a 182.78% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was $56.42M, a 37.26% decline from fiscal 2016.
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $89.92M.
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$292.35M.
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$123.44M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|---|
| 2018-03-31 | -$71.03M 10-Q · filed 2018-05-08 | -$13.92M derived: sum of 2 quarters · filed 2018-05-08 | $15.86M derived: sum of 3 quarters · filed 2018-05-08 | -$3.99M derived: sum of 4 quarters · filed 2018-05-08 | |
| 2017-12-31 | $57.10M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $86.89M derived: sum of 2 quarters · filed 2018-02-21 | $67.04M derived: sum of 3 quarters · filed 2018-02-21 | $56.42M 10-K · filed 2018-02-21 | |
| 2017-09-30 | $29.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $9.93M derived: sum of 2 quarters · filed 2017-11-03 | -$688.00K 10-Q · filed 2017-11-03 | -$9.04M derived: sum of 4 quarters · filed 2018-05-08 | |
| 2017-06-30 | -$19.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | -$30.48M 10-Q · filed 2017-07-28 | -$38.83M derived: sum of 3 quarters · filed 2018-05-08 | $13.68M derived: sum of 4 quarters · filed 2018-05-08 | |
| 2017-03-31 | -$10.62M 10-Q · filed 2018-05-08 | -$9.40M 10-Q · filed 2017-05-05 | -$18.98M derived: sum of 2 quarters · filed 2018-05-08 | $33.53M derived: sum of 3 quarters · filed 2018-05-08 | $57.52M derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | -$8.36M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $44.15M derived: sum of 2 quarters · filed 2018-02-21 | $68.14M derived: sum of 3 quarters · filed 2018-02-21 | $89.92M 10-K · filed 2018-02-21 | |
| 2016-09-30 | $52.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $76.50M derived: sum of 2 quarters · filed 2017-11-03 | $98.27M 10-Q · filed 2017-11-03 | $64.71M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2016-06-30 | $23.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $45.76M 10-Q · filed 2017-07-28 | $12.20M derived: sum of 3 quarters · filed 2018-02-21 | -$131.51M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2016-03-31 | $21.77M 10-Q · filed 2017-05-05 | -$11.79M derived: sum of 2 quarters · filed 2018-02-21 | -$155.50M derived: sum of 3 quarters · filed 2018-02-21 | -$266.51M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2015-12-31 | -$33.56M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | -$177.28M derived: sum of 2 quarters · filed 2018-02-21 | -$288.29M derived: sum of 3 quarters · filed 2018-02-21 | -$292.35M 10-K · filed 2018-02-21 | |
| 2015-09-30 | -$143.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | -$254.73M derived: sum of 2 quarters · filed 2016-11-08 | -$258.79M 10-Q · filed 2016-11-08 | -$275.81M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-06-30 | -$111.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$115.08M 10-Q · filed 2016-08-09 | -$132.10M derived: sum of 3 quarters · filed 2017-02-17 | -$145.64M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-03-31 | -$4.07M 10-Q · filed 2016-05-10 | -$21.09M derived: sum of 2 quarters · filed 2017-02-17 | -$34.63M derived: sum of 3 quarters · filed 2017-02-17 | -$62.11M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2014-12-31 | -$17.02M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | -$30.57M derived: sum of 2 quarters · filed 2017-02-17 | -$58.04M derived: sum of 3 quarters · filed 2017-02-17 | -$123.44M 10-K · filed 2017-02-17 | |
| 2014-09-30 | -$13.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | -$41.02M derived: sum of 2 quarters · filed 2015-11-10 | -$106.42M 10-Q · filed 2015-11-10 | ||
| 2014-06-30 | -$27.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | -$92.87M 10-Q · filed 2015-08-14 | |||
| 2014-03-31 | -$65.40M 10-Q · filed 2015-05-12 | ||||
| 2013-12-31 | -$47.73M 10-K · filed 2016-02-26 | ||||
| 2012-12-31 | -$1.19M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |